BioMarin Pharmaceutical Inc. (BMRN)
USD 60.58
(-10.23%)
USD 60.58
(-10.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 378.74 Million USD | 5.65% |
| 2022 | 358.48 Million USD | -27.11% |
| 2021 | 491.8 Million USD | 15.45% |
| 2020 | 425.98 Million USD | 3.73% |
| 2019 | 410.67 Million USD | 22.07% |
| 2018 | 336.43 Million USD | -41.64% |
| 2017 | 576.44 Million USD | 109.68% |
| 2016 | 274.9 Million USD | 3.64% |
| 2015 | 265.24 Million USD | 221.95% |
| 2014 | -217.51 Million USD | -350.63% |
| 2013 | 86.78 Million USD | -48.25% |
| 2012 | 167.69 Million USD | -44.48% |
| 2011 | 302.05 Million USD | 4.36% |
| 2010 | 289.44 Million USD | -12.27% |
| 2009 | 329.91 Million USD | 316.82% |
| 2008 | -152.15 Million USD | -155.26% |
| 2007 | 275.34 Million USD | 94.5% |
| 2006 | 141.56 Million USD | -23.96% |
| 2005 | 186.16 Million USD | -27.78% |
| 2004 | 257.76 Million USD | 7072.01% |
| 2003 | 3.59 Million USD | 114.07% |
| 2002 | -25.53 Million USD | -266.08% |
| 2001 | -6.97 Million USD | 57.58% |
| 2000 | -16.44 Million USD | 29.42% |
| 1999 | -23.3 Million USD | -150.56% |
| 1998 | -9.3 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 340.96 Million USD | 2.75% |
| 2024 Q3 | -80.82 Billion USD | -157.07% |
| 2024 Q2 | 127.49 Million USD | -62.61% |
| 2023 Q4 | 331.84 Million USD | 10.41% |
| 2023 Q3 | 300.57 Million USD | -23.05% |
| 2023 FY | 378.74 Million USD | 5.65% |
| 2023 Q2 | 390.61 Million USD | -22.49% |
| 2023 Q1 | 503.93 Million USD | 40.57% |
| 2022 Q4 | 358.48 Million USD | 11.85% |
| 2022 Q1 | 485.45 Million USD | -1.29% |
| 2022 Q3 | 320.51 Million USD | -30.51% |
| 2022 Q2 | 461.24 Million USD | -4.99% |
| 2022 FY | 358.48 Million USD | -27.11% |
| 2021 Q2 | 435.57 Million USD | 6.55% |
| 2021 Q1 | 408.81 Million USD | -4.03% |
| 2021 Q4 | 491.8 Million USD | 6.69% |
| 2021 FY | 491.8 Million USD | 15.45% |
| 2021 Q3 | 460.95 Million USD | 5.83% |
| 2020 Q2 | 624.4 Million USD | 66.04% |
| 2020 Q1 | 376.04 Million USD | -8.43% |
| 2020 Q3 | 432.77 Million USD | -30.69% |
| 2020 FY | 425.98 Million USD | 3.73% |
| 2020 Q4 | 425.98 Million USD | -1.57% |
| 2019 Q4 | 410.67 Million USD | -2.31% |
| 2019 FY | 410.67 Million USD | 22.07% |
| 2019 Q1 | 470.39 Million USD | 39.82% |
| 2019 Q2 | 531.58 Million USD | 13.01% |
| 2019 Q3 | 420.39 Million USD | -20.92% |
| 2018 Q3 | 318.16 Million USD | -58.37% |
| 2018 Q1 | 709.01 Million USD | 23.0% |
| 2018 FY | 336.43 Million USD | -41.64% |
| 2018 Q2 | 764.21 Million USD | 7.78% |
| 2018 Q4 | 336.43 Million USD | 5.74% |
| 2017 Q4 | 576.44 Million USD | -21.53% |
| 2017 Q3 | 734.63 Million USD | 128.62% |
| 2017 Q2 | 321.34 Million USD | -6.23% |
| 2017 Q1 | 342.69 Million USD | 24.66% |
| 2017 FY | 576.44 Million USD | 109.68% |
| 2016 Q1 | 397.55 Million USD | 49.88% |
| 2016 Q4 | 274.9 Million USD | 966.92% |
| 2016 Q2 | 364.13 Million USD | -8.41% |
| 2016 FY | 274.9 Million USD | 3.64% |
| 2016 Q3 | -31.71 Million USD | -108.71% |
| 2015 Q1 | -245.07 Million USD | -12.67% |
| 2015 FY | 265.24 Million USD | 221.95% |
| 2015 Q4 | 265.24 Million USD | -8.99% |
| 2015 Q2 | 220.82 Million USD | 190.1% |
| 2015 Q3 | 291.44 Million USD | 31.98% |
| 2014 Q4 | -217.51 Million USD | -184.02% |
| 2014 Q2 | 66.15 Million USD | 205.69% |
| 2014 FY | -217.51 Million USD | -350.63% |
| 2014 Q1 | 21.64 Million USD | -75.06% |
| 2014 Q3 | 258.87 Million USD | 291.32% |
| 2013 Q2 | -65.62 Million USD | -47.36% |
| 2013 Q1 | -44.53 Million USD | -126.55% |
| 2013 FY | 86.78 Million USD | -48.25% |
| 2013 Q3 | -103.25 Million USD | -57.35% |
| 2013 Q4 | 86.78 Million USD | 184.05% |
| 2012 Q1 | 265.74 Million USD | -12.02% |
| 2012 FY | 167.69 Million USD | -44.48% |
| 2012 Q4 | 167.69 Million USD | 0.43% |
| 2012 Q3 | 166.97 Million USD | -2.1% |
| 2012 Q2 | 170.54 Million USD | -35.82% |
| 2011 FY | 302.05 Million USD | 4.36% |
| 2011 Q4 | 302.05 Million USD | 9.01% |
| 2011 Q3 | 277.08 Million USD | 4.73% |
| 2011 Q1 | 286.73 Million USD | -0.93% |
| 2011 Q2 | 264.56 Million USD | -7.73% |
| 2010 Q1 | 388.12 Million USD | 17.64% |
| 2010 FY | 289.44 Million USD | -12.27% |
| 2010 Q2 | 381.3 Million USD | -1.76% |
| 2010 Q3 | 369.54 Million USD | -3.08% |
| 2010 Q4 | 289.44 Million USD | -21.68% |
| 2009 Q3 | 305.3 Million USD | 2.78% |
| 2009 FY | 329.91 Million USD | 316.82% |
| 2009 Q1 | 352.82 Million USD | 2.29% |
| 2009 Q2 | 297.03 Million USD | -15.81% |
| 2009 Q4 | 329.91 Million USD | 8.06% |
| 2008 Q3 | 226.02 Million USD | -9.9% |
| 2008 FY | -152.15 Million USD | -155.26% |
| 2008 Q1 | 183.37 Million USD | -33.4% |
| 2008 Q2 | 250.85 Million USD | 36.8% |
| 2008 Q4 | 344.92 Million USD | 52.61% |
| 2007 Q2 | 366.48 Million USD | 146.13% |
| 2007 Q3 | 279.04 Million USD | -23.86% |
| 2007 Q1 | 148.9 Million USD | 5.18% |
| 2007 Q4 | 275.34 Million USD | -1.33% |
| 2007 FY | 275.34 Million USD | 94.5% |
| 2006 FY | 141.56 Million USD | -23.96% |
| 2006 Q3 | 108.08 Million USD | 22.79% |
| 2006 Q2 | 88.02 Million USD | 65.48% |
| 2006 Q1 | 53.19 Million USD | -71.43% |
| 2006 Q4 | 141.56 Million USD | 30.97% |
| 2005 FY | 186.16 Million USD | -27.78% |
| 2005 Q4 | 186.16 Million USD | 9.56% |
| 2005 Q3 | 169.93 Million USD | -19.46% |
| 2005 Q2 | 210.99 Million USD | 33.2% |
| 2005 Q1 | 158.41 Million USD | -38.54% |
| 2004 Q1 | 28.8 Million USD | 701.36% |
| 2004 FY | 257.76 Million USD | 7072.01% |
| 2004 Q4 | 257.76 Million USD | 9.3% |
| 2004 Q3 | 235.82 Million USD | 69.96% |
| 2004 Q2 | 138.75 Million USD | 381.79% |
| 2003 Q3 | -62.97 Million USD | 34.92% |
| 2003 Q2 | -96.77 Million USD | 20.24% |
| 2003 Q1 | -121.33 Million USD | -326.67% |
| 2003 FY | 3.59 Million USD | 114.07% |
| 2003 Q4 | 3.59 Million USD | 105.71% |
| 2002 Q1 | -12.98 Million USD | -86.08% |
| 2002 Q4 | -28.43 Million USD | 3.58% |
| 2002 FY | -25.53 Million USD | -266.08% |
| 2002 Q2 | -15.86 Million USD | -22.2% |
| 2002 Q3 | -29.49 Million USD | -85.92% |
| 2001 Q1 | -19.64 Million USD | -19.45% |
| 2001 Q2 | -18.67 Million USD | 4.96% |
| 2001 Q3 | -6.98 Million USD | 62.57% |
| 2001 Q4 | -6.97 Million USD | 0.19% |
| 2001 FY | -6.97 Million USD | 57.58% |
| 2000 Q1 | -40.57 Million USD | -74.11% |
| 2000 FY | -16.44 Million USD | 29.42% |
| 2000 Q4 | -16.44 Million USD | -2.75% |
| 2000 Q3 | -16 Million USD | -52.27% |
| 2000 Q2 | -10.51 Million USD | 74.09% |
| 1999 Q2 | 8.9 Million USD | 354.29% |
| 1999 Q4 | -23.3 Million USD | 28.3% |
| 1999 FY | -23.3 Million USD | -150.56% |
| 1999 Q3 | -32.5 Million USD | -465.17% |
| 1999 Q1 | -3.5 Million USD | 0.0% |
| 1998 FY | -9.3 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 777.061% |
| Alkermes plc | -166.73 Million USD | 327.15% |
| Agenus Inc. | 274.13 Million USD | -38.161% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 79.745% |
| Aptorum Group Limited | 1.35 Million USD | -27809.739% |
| Ardelyx, Inc. | 34.51 Million USD | -997.439% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -8749.252% |
| Bicycle Therapeutics plc | -481.46 Million USD | 178.665% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -947.336% |
| ChromaDex Corporation | -24.04 Million USD | 1674.967% |
| Chimerix, Inc. | -25.51 Million USD | 1584.297% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -5335.475% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 1699.645% |
| CRISPR Therapeutics AG | -150.84 Million USD | 351.084% |
| Precision BioSciences, Inc. | -85.41 Million USD | 543.447% |
| Dyadic International, Inc. | -6.37 Million USD | 6038.258% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 2477.129% |
| Fortress Biotech, Inc. | 7.66 Million USD | -4841.265% |
| Lantern Pharma Inc. | -21.7 Million USD | 1845.119% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 442.644% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 4533.34% |
| Incyte Corporation | -3.17 Billion USD | 111.929% |
| IO Biotech, Inc. | -140.69 Million USD | 369.19% |
| Jaguar Health, Inc. | 29.39 Million USD | -1188.653% |
| Novavax, Inc. | -298.29 Million USD | 226.971% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -6996.646% |
| Opthea Limited | 28.15 Million USD | -1245.108% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 2355.929% |
| ContextLogic Inc. | -232 Million USD | 263.253% |
| MiMedx Group, Inc. | -33.9 Million USD | 1217.218% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -3615.037% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 16446.292% |
| NextCure, Inc. | -6.47 Million USD | 5947.584% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 849.981% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 6037.42% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -3013.867% |
| Vaxcyte, Inc. | -368.22 Million USD | 202.857% |
| PDS Biotechnology Corporation | -32.7 Million USD | 1257.936% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -2092.082% |
| Pharming Group N.V. | 109.8 Million USD | -244.931% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 2277.213% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 316.143% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 2145.091% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 2145.091% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 5434.479% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 6563.276% |
| Acelyrin, Inc. | -216.9 Million USD | 274.616% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 6850.98% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 22069.142% |
| Summit Therapeutics Inc. | 34.67 Million USD | -992.311% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 5667.367% |
| Senti Biosciences, Inc. | 1.74 Million USD | -21667.126% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 305.164% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 589.016% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 6347.905% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -379524.934% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -60210.191% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 423.589% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 325.133% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -241.615% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 5086.151% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 393.344% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -5393.402% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 256.273% |
| Immix Biopharma, Inc. | -17.5 Million USD | 2263.064% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 219.591% |
| MEI Pharma, Inc. | -3.7 Million USD | 10322.618% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -2927.32% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | -134.168% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -1262.746% |
| Fortress Biotech, Inc. | 7.66 Million USD | -4841.265% |
| Precigen, Inc. | -481 Thousand USD | 78841.788% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -2589.781% |
| AlloVir, Inc. | -62.69 Million USD | 704.141% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 781.03% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -514.193% |
| ImmuCell Corporation | 10.99 Million USD | -3346.12% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 345.707% |
| Onconetix, Inc. | 5.33 Million USD | -7004.051% |
| PureTech Health plc | -167.19 Million USD | 326.528% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 1343.427% |
| Elevation Oncology, Inc. | -19.11 Million USD | 2081.107% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 7815.38% |
| Seer, Inc. | -4.24 Million USD | 9032.736% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 1675.687% |
| Innoviva, Inc. | 255.56 Million USD | -48.201% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 777.982% |
| ESSA Pharma Inc. | -33.62 Million USD | 1226.503% |
| GlycoMimetics, Inc. | -40.98 Million USD | 1024.127% |
| GT Biopharma, Inc. | -1.02 Million USD | 37195.788% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 658.765% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -518.293% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 382.481% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 2833.458% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 1411.818% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 502858.383% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 1327.231% |
| Aptose Biosciences Inc. | -8.19 Million USD | 4721.777% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 12204.373% |
| Soligenix, Inc. | -4.95 Million USD | 7749.007% |
| Century Therapeutics, Inc. | 847 Thousand USD | -44616.411% |
| Kura Oncology, Inc. | -20.11 Million USD | 1982.632% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 1025.446% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 4609.979% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -20690.967% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 11946.982% |
| Autolus Therapeutics plc | -186.59 Million USD | 302.974% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 868.189% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 237.33% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -1005.253% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | -130.427% |
| GRI Bio, Inc. | -1.79 Million USD | 21211.929% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 4316.254% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 1238.852% |
| IGM Biosciences, Inc. | -72.6 Million USD | 621.648% |
| INmune Bio, Inc. | -25.41 Million USD | 1590.488% |
| Heron Therapeutics, Inc. | 150.95 Million USD | -150.908% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 847.642% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 2430.847% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 13228.517% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -896.312% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 1019.626% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -1087.856% |
| Coherus BioSciences, Inc. | 377.95 Million USD | -0.211% |
| Verastem, Inc. | -37.27 Million USD | 1116.009% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 4274.452% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 830.3% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 2602.464% |
| Histogen Inc. | -7.48 Million USD | 5158.742% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 1852.909% |
| Surrozen, Inc. | -32.66 Million USD | 1259.527% |
| Organovo Holdings, Inc. | -1.5 Million USD | 25232.581% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 9110.327% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -1897.594% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -14378.135% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -9013.282% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 4619.046% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 971.848% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 2698.282% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 219.558% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 52553.813% |
| Apollomics, Inc. | -27.39 Million USD | 1482.544% |
| Amarin Corporation plc | -191.04 Million USD | 298.256% |
| Mesoblast Limited | 55.96 Million USD | -576.783% |
| Turnstone Biologics Corp. | -14.58 Million USD | 2697.01% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 1597.501% |
| Synaptogenix, Inc. | -28.66 Million USD | 1421.452% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 40564.53% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -677.206% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 44033.747% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 5312.549% |
| Exelixis, Inc. | -73.05 Million USD | 618.478% |
| Better Therapeutics, Inc. | -860 Thousand USD | 44140.465% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 1677.262% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 256.915% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -51355.712% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 5191.975% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -30103.19% |
| Gritstone bio, Inc. | 39.49 Million USD | -859.099% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 550.349% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 14489.356% |
| Avid Bioservices, Inc. | 169.72 Million USD | -123.15% |
| Insmed Incorporated | 721.62 Million USD | 47.514% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 4243.166% |
| MediWound Ltd. | -5.32 Million USD | 7216.648% |
| OmniAb, Inc. | 9.2 Million USD | -4015.484% |
| Alector, Inc. | -35.63 Million USD | 1162.794% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -340.553% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 7785.633% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -2760.851% |
| Zai Lab Limited | -775 Million USD | 148.871% |
| Revance Therapeutics, Inc. | 340.55 Million USD | -11.215% |
| Aura Biosciences, Inc. | -21.52 Million USD | 1859.573% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 559.2% |
| Immunic, Inc. | -45.34 Million USD | 935.351% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 296.024% |
| Veracyte, Inc. | -203.82 Million USD | 285.821% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 40.662% |
| FibroGen, Inc. | 56.76 Million USD | -567.197% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -4153.206% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 13497.135% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 18393.929% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 91.749% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 11436.366% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 328.211% |
| TG Therapeutics, Inc. | 17.86 Million USD | -2020.412% |
| Galecto, Inc. | -21.21 Million USD | 1885.2% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 1692.382% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 75.867% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 1647.679% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 3391.457% |
| XBiotech Inc. | -200.02 Million USD | 289.352% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 550.349% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -8264.576% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 1174.066% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 590.492% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -6555.21% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 322.25% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 510.016% |
| Vaxxinity, Inc. | 10.13 Million USD | -3638.137% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 48.558% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 3617.494% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 674.243% |
| NexImmune, Inc. | -3.13 Million USD | 12186.508% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 11069.704% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 2606.364% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 1497.594% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 4319.538% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 304132.109% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 1033.521% |
| Ainos, Inc. | 4.07 Million USD | -9187.756% |
| Pluri Inc. | 22.82 Million USD | -1559.065% |
| Prothena Corporation plc | -608.34 Million USD | 162.259% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 418.93% |
| Celularity Inc. | 65.19 Million USD | -480.991% |
| Rallybio Corporation | -24.1 Million USD | 1671.438% |
| Cue Biopharma, Inc. | -33.81 Million USD | 1219.927% |
| MeiraGTx Holdings plc | -40.3 Million USD | 1039.775% |
| Omeros Corporation | 331.17 Million USD | -14.365% |
| Humacyte, Inc. | -22.48 Million USD | 1784.372% |
| Immunocore Holdings plc | -358.59 Million USD | 205.62% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 1641.192% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 1325.682% |
| Blueprint Medicines Corporation | 702.83 Million USD | 46.111% |
| CalciMedica, Inc. | -5.53 Million USD | 6948.969% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 301.226% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 3808.126% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 1045.995% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 1238.989% |
| Pulmatrix, Inc. | -10.41 Million USD | 3735.864% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 6436.758% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 1092.995% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 439.983% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 731.836% |
| Cytokinetics, Incorporated | 642.37 Million USD | 41.039% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 6604.345% |
| Nutriband Inc. | -251.65 Thousand USD | 150601.675% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 1210.079% |
| Vor Biopharma Inc. | 4.3 Million USD | -8708.093% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 106.275% |
| Evogene Ltd. | -19.63 Million USD | 2029.041% |
| ProKidney Corp. | -56.23 Million USD | 773.497% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 878.164% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 4200.253% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 72.231% |
| CorMedix Inc. | -43.05 Million USD | 979.735% |
| BioLineRx Ltd. | 7.33 Million USD | -5062.868% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 1479.021% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -720.742% |
| Atai Life Sciences N.V. | -28.55 Million USD | 1426.241% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -16880.187% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 1760.011% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -2035.596% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 604.5% |
| MediciNova, Inc. | -50.78 Million USD | 845.809% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 580.614% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 1683798.6% |
| GeoVax Labs, Inc. | -6.45 Million USD | 5969.706% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 289.544% |
| Biomea Fusion, Inc. | -166.57 Million USD | 327.381% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 311.621% |
| Mereo BioPharma Group plc | -51.46 Million USD | 835.876% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 499.338% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 228.932% |
| Absci Corporation | -72.59 Million USD | 621.706% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -8194.963% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 261.556% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 502.021% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 495.782% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 1069.334% |
| Allakos Inc. | -24.97 Million USD | 1616.509% |
| Imunon, Inc. | -4.21 Million USD | 9088.166% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 2669.177% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 379.725% |
| BioAtla, Inc. | -109.01 Million USD | 447.44% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -51355.712% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 40435.25% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -3065.201% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 1886.294% |
| XOMA Corporation | -29 Million USD | 1406.028% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 2387.126% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 4300.843% |
| aTyr Pharma, Inc. | -7.44 Million USD | 5184.548% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 403.883% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 281.947% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 563.136% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 508.296% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 44182.292% |
| Akari Therapeutics, Plc | -3.84 Million USD | 9950.403% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -23237.873% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 72.572% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 31977.522% |
| UroGen Pharma Ltd. | 4.39 Million USD | -8525.552% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -233.755% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -526216.667% |
| Orgenesis Inc. | 21.78 Million USD | -1638.652% |
| Entera Bio Ltd. | -10.62 Million USD | 3663.346% |
| GH Research PLC | -78.07 Million USD | 585.095% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 1799.336% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 1520.713% |
| Xencor, Inc. | 29.64 Million USD | -1177.655% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 19327.622% |
| Replimune Group, Inc. | 1.41 Million USD | -26723.513% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 154749.093% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 399.602% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 31977.522% |
| Portage Biotech Inc. | -4.98 Million USD | 7703.855% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 1683798.6% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 672.802% |
| OncoCyte Corporation | -6.56 Million USD | 5870.958% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -42104.425% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 8413.821% |
| Purple Biotech Ltd. | -14.13 Million USD | 2778.936% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 1694.326% |
| scPharmaceuticals Inc. | -6.54 Million USD | 5886.83% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 2369.017% |
| HilleVax, Inc. | -165.48 Million USD | 328.871% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 15023.089% |
| Tharimmune, Inc. | -10.93 Million USD | 3563.519% |
| Genprex, Inc. | -6.73 Million USD | 5721.384% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 202.695% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 528.157% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 27134.118% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 11518.576% |
| OKYO Pharma Limited | -826.84 Thousand USD | 45906.243% |
| Savara Inc. | 153 Thousand USD | -247447.712% |
| Curis, Inc. | -23.88 Million USD | 1685.582% |
| Daré Bioscience, Inc. | -5.15 Million USD | 7443.05% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 48906.977% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 6200.966% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -31861.857% |
| BeiGene, Ltd. | -2.25 Billion USD | 116.81% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -2969.644% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 162.273% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 304.082% |
| Erasca, Inc. | -37.21 Million USD | 1117.702% |
| bluebird bio, Inc. | 108.57 Million USD | -248.848% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 29508.344% |
| DBV Technologies S.A. | -126.98 Million USD | 398.26% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 29508.344% |
| Moderna, Inc. | -2.9 Billion USD | 113.029% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 3758.694% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 3584.983% |
| Molecular Templates, Inc. | 707 Thousand USD | -53471.146% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 1307.319% |
| Travere Therapeutics, Inc. | 346.6 Million USD | -9.273% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 561.539% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 512.894% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 1273.612% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 1201.78% |
| MacroGenics, Inc. | -66.98 Million USD | 665.422% |
| RenovoRx, Inc. | -1.17 Million USD | 32388.832% |
| Adicet Bio, Inc. | -138.78 Million USD | 372.899% |
| Prime Medicine, Inc. | -27.94 Million USD | 1455.528% |
| Aditxt, Inc. | 18.12 Million USD | -1990.119% |
| Adagene Inc. | -87.62 Million USD | 532.226% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 9192.655% |
| Quantum-Si incorporated | -118.55 Million USD | 419.465% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -951.932% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 5167.413% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 880.779% |
| SciSparc Ltd. | -2.06 Million USD | 18441.308% |
| Vericel Corporation | 1.27 Million USD | -29559.201% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 3258.418% |
| Minerva Neurosciences, Inc. | 41 Million USD | -823.68% |
| Generation Bio Co. | 31.44 Million USD | -1104.363% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 315.978% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 1324.81% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -224.846% |
| Invivyd, Inc. | -198.47 Million USD | 290.828% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 519.572% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 15896.382% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 635.03% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 5649.421% |
| 2seventy bio, Inc. | 181.71 Million USD | -108.43% |
| ADMA Biologics, Inc. | 90.06 Million USD | -320.523% |
| Clene Inc. | 3.34 Million USD | -11239.76% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 4269.992% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 1860.718% |
| GeoVax Labs, Inc. | -6.45 Million USD | 5969.706% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 210.061% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 1556.741% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | -113.18% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 9356.796% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -7471.931% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 7371.031% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 390.665% |
| Evaxion Biotech A/S | 5.28 Million USD | -7063.972% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 436.462% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 388.519% |
| Trevena, Inc. | 2.25 Million USD | -16673.605% |
| Surrozen, Inc. | -32.66 Million USD | 1259.527% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 835.29% |
| Cingulate Inc. | 3.08 Million USD | -12186.31% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 12995.744% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -5169.904% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 4176.405% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 577.476% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 388.126% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 458.86% |
| Clearmind Medicine Inc. | -3.94 Million USD | 9706.464% |
| Kronos Bio, Inc. | -36.05 Million USD | 1150.502% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -3925.38% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -25874.967% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 798.076% |
| Statera Biopharma, Inc. | 14.41 Million USD | -2527.201% |
| ImmunityBio, Inc. | 618.22 Million USD | 38.736% |
| Korro Bio, Inc. | -132.94 Million USD | 384.895% |
| Kineta, Inc. | -4.54 Million USD | 8440.63% |
| BioVie Inc. | -17.73 Million USD | 2235.915% |
| Codexis, Inc. | -43.27 Million USD | 975.293% |
| Celularity Inc. | 65.19 Million USD | -480.991% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 12051.657% |
| Celcuity Inc. | 6.78 Million USD | -5483.364% |
| Virax Biolabs Group Limited | -3.36 Million USD | 11355.7% |
| Cibus, Inc. | -8.07 Million USD | 4788.636% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 9055.971% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -8187.702% |
| IN8bio, Inc. | -16.38 Million USD | 2410.989% |
| Kodiak Sciences Inc. | -103.87 Million USD | 464.619% |
| Annexon, Inc. | -193.75 Million USD | 295.478% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -1051977.778% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 2264.398% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 10881.327% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 64.075% |
| Eyenovia, Inc. | 1.25 Million USD | -29990.363% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -1307.723% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 11778.939% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 1239.195% |
| Arcellx, Inc. | -296.95 Million USD | 227.543% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 2041.7% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 743.309% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 1927.317% |
| Moolec Science SA | 117.61 Thousand USD | -321920.813% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 1086.349% |
| Geron Corporation | 14.76 Million USD | -2465.87% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 1098.861% |
| Royalty Pharma plc | 5.65 Billion USD | 93.306% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 367.816% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 5518.873% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 7162.427% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 369.129% |
| Humacyte, Inc. | -22.48 Million USD | 1784.372% |
| Structure Therapeutics Inc. | -124.33 Million USD | 404.609% |
| 89bio, Inc. | -289.05 Million USD | 231.031% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 1600.467% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 21342.176% |
| Genelux Corporation | -6.89 Million USD | 5589.897% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 1319.447% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -353.053% |
| Notable Labs, Ltd. | -9.77 Million USD | 3974.264% |
| Liquidia Corporation | -80.17 Million USD | 572.396% |
| Mustang Bio, Inc. | -3.73 Million USD | 10237.794% |
| Immunovant, Inc. | -635.22 Million USD | 159.624% |
| Quantum-Si incorporated | -118.55 Million USD | 419.465% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 2256.388% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 9241.878% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -4618.425% |
| Acasti Pharma Inc. | -23 Million USD | 1746.373% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 11348.062% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 2430.847% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 374.973% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 12253.53% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 1803.616% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 2139.679% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 323.743% |
| PepGen Inc. | -60.67 Million USD | 724.276% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 1748.451% |
| United Therapeutics Corporation | -507.7 Million USD | 174.601% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 2080.278% |
| Solid Biosciences Inc. | -47.75 Million USD | 893.19% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 44033.747% |
| Immuneering Corporation | -54.94 Million USD | 789.349% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 9110.327% |
| Silo Pharma, Inc. | -3.52 Million USD | 10846.734% |
| Belite Bio, Inc | -87.27 Million USD | 533.991% |
| XOMA Corporation | -29 Million USD | 1406.028% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 635.734% |
| Bionomics Limited | 227 Million USD | -66.842% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 425.715% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 15052.546% |
| uniQure N.V. | -102.95 Million USD | 467.892% |
| Cassava Sciences, Inc. | -121.13 Million USD | 412.663% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 9192.655% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -824.881% |
| Forte Biosciences, Inc. | -11.96 Million USD | 3266.525% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 12340.579% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -357209.434% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 11778.939% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -4153.206% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 5207.174% |
| Altimmune, Inc. | -134.48 Million USD | 381.624% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -91.224% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 15052.546% |
| Compugen Ltd. | -12.9 Million USD | 3035.121% |
| Peak Bio, Inc. | 10.34 Million USD | -3562.884% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 133933.216% |
| Benitec Biopharma Inc. | -50.58 Million USD | 848.78% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 463.001% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -1827.961% |
| Zura Bio Limited | -99.8 Million USD | 479.484% |
| PolyPid Ltd. | 6.17 Million USD | -6038.541% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -410.993% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -1827.961% |
| Instil Bio, Inc. | 75.35 Million USD | -402.598% |
| argenx SE | -2.02 Billion USD | 118.668% |
| Immunome, Inc. | -97.02 Million USD | 490.345% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 1783.699% |
| Verona Pharma plc | -220.44 Million USD | 271.812% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 627.923% |
| Shattuck Labs, Inc. | -121.42 Million USD | 411.922% |
| CervoMed Inc. | -7.79 Million USD | 4960.201% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 304.178% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 8761.056% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 387.497% |
| Moolec Science SA | 117.61 Thousand USD | -321920.813% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 16653.838% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -2282.306% |
| AnaptysBio, Inc. | -18.15 Million USD | 2186.651% |
| Design Therapeutics, Inc. | -18.15 Million USD | 2186.766% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 638.14% |
| NeurAxis, Inc. | 145.7 Thousand USD | -259850.583% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -3272.044% |
| Lumos Pharma, Inc. | -28.49 Million USD | 1429.267% |
| Achilles Therapeutics plc | -126.92 Million USD | 398.405% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 627.923% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 57859.749% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 1923.198% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -25874.967% |
| Nutriband Inc. | -251.65 Thousand USD | 150601.675% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 2975.621% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 5190.699% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | -11.332% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -1495.736% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 184.642% |
| Palisade Bio, Inc. | -12.06 Million USD | 3239.75% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 369.935% |
| Beam Therapeutics Inc. | -262.72 Million USD | 244.163% |
| Neurogene Inc. | -131.95 Million USD | 387.028% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -1636.102% |
| AEON Biopharma, Inc. | -4.88 Million USD | 7861.23% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 200.413% |
| Sesen Bio, Inc. | -112.55 Million USD | 436.506% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 479.279% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 16232.087% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 1070.502% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 554.778% |
| Athira Pharma, Inc. | -88.99 Million USD | 525.564% |
| Vaccinex, Inc. | -1.28 Million USD | 29505.901% |
| HCW Biologics Inc. | 2.85 Million USD | -13158.346% |
| XOMA Corporation | -29 Million USD | 1406.028% |
| Nektar Therapeutics | 210.24 Million USD | -80.15% |
| Arvinas, Inc. | -313.8 Million USD | 220.697% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -23237.873% |
| Merus N.V. | -192.88 Million USD | 296.361% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -531.405% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 5559.037% |
| Rezolute, Inc. | -68.16 Million USD | 655.61% |
| Clene Inc. | 3.34 Million USD | -11239.76% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 2972.132% |
| BeyondSpring Inc. | -13.75 Million USD | 2853.53% |
| Synlogic, Inc. | -6.68 Million USD | 5765.639% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -33299.295% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 4579.574% |
| Peak Bio, Inc. | 10.34 Million USD | -3562.884% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 559.534% |
| Krystal Biotech, Inc. | -350.23 Million USD | 208.141% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -205.134% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 324.117% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 12096.539% |
| MannKind Corporation | 143.89 Million USD | -163.204% |
| Ikena Oncology, Inc. | -109.15 Million USD | 446.979% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 5102.615% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 1244.254% |
| Gossamer Bio, Inc. | 180.35 Million USD | -110.001% |
| CohBar, Inc. | -5.93 Million USD | 6486.194% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 1373.188% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -8194.963% |
| Legend Biotech Corporation | -949.39 Million USD | 139.893% |
| Mural Oncology plc | -255.84 Million USD | 248.039% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -1075.688% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 8140.263% |
| Disc Medicine, Inc. | -358.28 Million USD | 205.713% |
| Champions Oncology, Inc. | 4.81 Million USD | -7770.906% |
| REGENXBIO Inc. | 54.76 Million USD | -591.55% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 140947.207% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 350.787% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 4302.705% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 569.427% |
| Vaxart, Inc. | -8.24 Million USD | 4695.899% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 854.779% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 397.838% |
| Cellectis S.A. | -43.85 Million USD | 963.637% |
| Longeveron Inc. | -2.9 Million USD | 13124.347% |
| Repare Therapeutics Inc. | -107.85 Million USD | 451.154% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 60.888% |
| Inozyme Pharma, Inc. | 12 Million USD | -3055.182% |
| Revolution Medicines, Inc. | -608.2 Million USD | 162.273% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 30892.52% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 242.861% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 352.378% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 2520.579% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 51282.162% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 103.96% |
| Denali Therapeutics Inc. | -74.86 Million USD | 605.908% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 3258.418% |
| Veru Inc. | 4.77 Million USD | -7823.65% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 3467.846% |
| Cingulate Inc. | 3.08 Million USD | -12186.31% |
| Passage Bio, Inc. | 4.58 Million USD | -8160.589% |
| Context Therapeutics Inc. | -14.44 Million USD | 2721.125% |
| Exicure, Inc. | 5.84 Million USD | -6375.432% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 264.404% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 1057.159% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -2313.791% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 743.899% |
| Nuvalent, Inc. | -335.38 Million USD | 212.929% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -21738.151% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 608.509% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 4360.382% |
| OmniAb, Inc. | 9.2 Million USD | -4015.484% |
| Anew Medical, Inc. | 1.43 Million USD | -26340.297% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -2212.011% |
| Lipocine Inc. | -4.75 Million USD | 8065.941% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 444.856% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -2386.692% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 847.642% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -1421.565% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 5735.292% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 675.369% |
| Ocugen, Inc. | -32.52 Million USD | 1264.626% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 542.592% |
| Q32 Bio Inc. | -37.94 Million USD | 1098.071% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 60410.191% |
| Alumis Inc. Common Stock | -13.52 Million USD | 2899.527% |
| Equillium, Inc. | -22.39 Million USD | 1791.443% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 1581.336% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 1260.851% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 152873.33% |
| Galera Therapeutics, Inc. | 134.04 Million USD | -182.559% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -11743.277% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -115216.906% |
| Dominari Holdings Inc. | 195 Thousand USD | -194129.744% |
| Edesa Biotech, Inc. | -5.26 Million USD | 7291.085% |
| vTv Therapeutics Inc. | -8.91 Million USD | 4347.482% |
| Bio-Techne Corporation | 267.74 Million USD | -41.457% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 2436.652% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 420.717% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 4607.295% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 3093.819% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 254.516% |
| Nkarta, Inc. | 57.29 Million USD | -561.003% |
| BioCardia, Inc. | 212 Thousand USD | -178554.717% |
| Iterum Therapeutics plc | 13.43 Million USD | -2718.485% |